Opinion|Videos|June 12, 2025
Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management
Panelists discuss how future research priorities for tarlatamab focus on optimizing administration, improving toxicity management, and enhancing patient selection, with an emphasis on minimizing adverse events while maximizing efficacy and evaluating long-term safety.
Advertisement
Episodes in this series
Summary for Physicians:
Future Research Priorities:
- Optimizing tarlatamab administration:
- Investigate dose optimization and scheduling to maximize efficacy while minimizing toxicity.
- Explore combination therapies with other immunotherapies or targeted agents for synergistic effects.
- Toxicity management:
- Develop predictive biomarkers for early detection of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome.
- Improve management protocols to reduce the incidence of severe toxicities.
- Investigate strategies to minimize neurological and immune-related adverse events without compromising efficacy.
Long-Term Goals:
- Enhance patient selection strategies to identify those most likely to benefit from tarlatamab.
Evaluate long-term safety and effectiveness in real-world settings.
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.
Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.
Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.
Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.
The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Findings from the phase 3 VOLGA trial support the FDA approval of perioperative durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5